You are here: Industry Insights > Chiesi

News List

Protalix BioTherapeutics, Chiesi Complete Enrollment for Trial of Pegunigalsidase Alfa americanpharmaceuticalreview
September 25, 2019
Protalix BioTherapeutics and its development and commercialization partner, Chiesi Farmaceutici announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa ...
Santhera, Chiesi Group Enter Raxone License Agreement contractpharma
May 29, 2019
Chiesi gains rights to Raxone in LHON and all other ophthalmological indications in deal valued at €186 million.
Pharmaxis Announces Resubmission of Bronchitol NDA drugs
December 26, 2018
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the resubmission of the Bronchitol New Drug Application with the United States Food and Drug Administration (FDA) by its licensee Chiesi Group (Chiesi).
One in three COPD patients believe they would get better care with different disease pharmatimes
November 26, 2018
One third of patients with chronic obstructive pulmonary disease (COPD) feel they would receive better care if they had cancer, diabetes or heart disease, according to a new Chiesi-sponsored patient survey.
EU green light for Chiesi’s Lamzede pharmatimes
July 18, 2018
European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
EU nod for Chiesi’s COPD therapy pharmatimes
July 27, 2017
European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.

Previous page 1 2 Next page